

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Results of the Phase III Impassion 130 trial, which were presented at ESMO 2018 and published in *The New England Journal of Medicine*, demonstrated a statistically significant improvement in _____ with the addition of atezolizumab to *nab* paclitaxel as first-line treatment for advanced TNBC.
 - a. Overall survival
 - b. Progression-free survival
 - c. Both a and b
 - d. Neither a nor b
2. The TEXT and SOFT trials reported a statistically significant improvement in freedom from distant recurrence among premenopausal women with ER-positive BC who received exemestane and ovarian function suppression compared to tamoxifen alone.
 - a. True
 - b. False
3. Results from the Phase II PERTAIN study for ER-positive, HER2-positive locally advanced or metastatic BC demonstrated a statistically significant improvement in progression-free survival with the addition of _____ to first-line trastuzumab and an aromatase inhibitor.
 - a. Neratinib
 - b. Pertuzumab
 - c. Pembrolizumab
4. The APHINITY trial investigating the addition of pertuzumab to adjuvant trastuzumab and chemotherapy for HER2-positive early BC demonstrated better outcomes for patients with node-negative BC than for those with node-positive BC.
 - a. True
 - b. False
5. The ongoing Phase II HER2CLIMB study is evaluating the addition of tucatinib to _____ for advanced HER2-positive BC.
 - a. Capecitabine
 - b. Trastuzumab
 - c. Both a and b
6. In the Phase III TAILORx study for patients with node-negative, hormone receptor-positive, HER2-negative BC and an intermediate RS of 11 to 25, adjuvant endocrine therapy alone was _____ to endocrine therapy with chemotherapy in terms of invasive disease-free survival in the postmenopausal population.
 - a. Inferior
 - b. Noninferior
7. Patients who are pregnant and have been diagnosed with HER2-positive BC _____.
 - a. Can receive trastuzumab/pertuzumab with chemotherapy during pregnancy
 - b. Can receive chemotherapy during the second and third trimesters followed by trastuzumab/pertuzumab after delivery
8. Which Phase III trial is evaluating T-DM1 versus trastuzumab as adjuvant therapy for patients with HER2-positive early BC and residual disease after preoperative therapy?
 - a. APHINITY
 - b. HER2CLIMB
 - c. KATHERINE
9. Which of the following categories reflects the mechanism of action of tucatinib?
 - a. Antibody-drug conjugate
 - b. Anti-PD-1/PD-L1 antibody
 - c. CDK4/6 inhibitor
 - d. Tyrosine kinase inhibitor
10. Results from the Phase III PALOMA-3 study, which were presented at ESMO 2018 and published in *The New England Journal of Medicine*, included a statistically significant improvement in overall survival with the addition of palbociclib to fulvestrant for patients with hormone receptor-positive, HER2-negative advanced BC who were sensitive to previous endocrine therapy.
 - a. True
 - b. False